Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bclx-vMO
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Likely Intravenous, Possibly Intratumoral Or Other Parenteral Routes Depending On Formulation And Study Design
01
Overview
Bclx-vMO is an experimental antisense oligonucleotide designed to target the mRNA of the anti-apoptotic protein BCL-XL (also known as BCL2-like 1 or BCL2L1). By binding to the pre-mRNA of BCL-XL, this morpholino oligonucleotide (vMO) inhibits its proper splicing and expression, thereby reducing levels of the functional anti-apoptotic protein in cells. The reduction of BCL-XL sensitizes cancer cells to apoptosis, particularly in tumors that are dependent on this protein for survival and resistance to chemotherapy. This approach is being explored as a targeted therapy for various cancers where overexpression of BCL-XL contributes to tumorigenesis and drug resistance[3][4]. The vMO (vivo-morpholino) chemistry allows for improved delivery into cells compared with standard morpholinos.
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on Bclx-vMO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bclx-vMO.